What is ipamorelin? It was tested in a randomized trial and missed its endpoints

The unusual thing about ipamorelin

Most peptides sold online have never been near a randomized human trial. Their evidence stops at cells, animals, or small volunteer studies measuring blood levels.

Ipamorelin is different, and not in the way sellers would like.

It reached a randomized phase 2 trial in people. The trial missed its endpoints.

The study looked at postoperative ileus, which is the temporary shutdown of gut motility that can follow abdominal surgery. That's a sensible target given how the compound works.

The result: no statistically significant improvement in its key or secondary efficacy endpoints.²

Not a mixed result. Not promising-but-underpowered. The primary endpoint and the secondary endpoints both came back without a significant improvement.

Why a negative trial is more informative than no trial

This sounds like bad news for the compound, and it is. It's also better evidence than almost anything else in this category has, which is worth sitting with.

Compare the three positions a compound can be in:

Most research peptides sit in row one, where the absence of evidence gets read as room for optimism. Ipamorelin sits in row two, and row two is knowledge.

So the accurate description isn't "untested." It's tested for one thing and it didn't work for that thing.

That's narrower than "ipamorelin doesn't work," and it's much more than can be said about most of what it sits next to on a vendor page. We work through this ranking in why evidence maturity beats online momentum.

How it works

Ipamorelin is a ghrelin-receptor agonist, also called a growth-hormone secretagogue.

Ghrelin is the hormone most people know as the hunger signal. It also acts on a receptor in the pituitary that triggers growth hormone release, and it influences how the gut moves things along.

Our profile describes ipamorelin as activating the ghrelin or growth-hormone-secretagogue receptor, stimulating GH release and gastrointestinal motility pathways.

That gut-motility half explains the postoperative-ileus trial. It was a reasonable hypothesis tested properly.

Early volunteer studies establish pharmacology, not wellness benefit. They show the compound does what its mechanism predicts to hormone levels. They don't show that anything improves as a result.

That's the same surrogate-marker gap we describe for CJC-1295, which is the compound ipamorelin is most often paired with.

We rate it low evidence with an early signal in our research directory.

The market: cheap, crowded, barely tested

Ipamorelin runs $17.56 to $105.00 across 20 vendors, as of our 25 July 2026 check.

That $17.56 floor is among the lowest of anything in our price market.

Cheap and widely available reads as low-stakes, and it shouldn't. Price in this market reflects supply and competition, not quality or evidence. Nothing about a $17 vial tells you what's in it.

Our testing ledger holds three published lab records for ipamorelin.³

Two of those are tight. The third is 20% over on a 5mg vial.

Worth noting that the dose accuracy here is generally better than what we see on the GLP-1 side, where tirzepatide runs a median of +13.1% over label. But three records cannot characterise what 20 vendors ship, and one of the three names no vendor on its source listing at all.

Where ipamorelin sits

It has real human trial evidence, and that evidence is negative for the condition studied.

The pharmacology is established. It acts on the ghrelin receptor and raises growth hormone. That's a measurement.

No approval, anywhere, and none of the uses it's marketed for have been established.¹

Cheap and crowded, 20 sellers from $17.56, on three published lab records.

The interesting question isn't whether ipamorelin works. It's why a compound with a failed randomized trial behind it is still sold by twenty vendors, and the answer has nothing to do with the evidence.

Next: CJC-1295, its usual pairing. Profile with graded outcomes and sources: ipamorelin.